Galderma reported first-half 2026 net sales of $3.134 billion, a 24.6% increase at constant currency, prompting the company to raise its full-year guidance. The surge reflects sustained demand across its portfolio, including continued momentum in neuromodulators and dermal fillers alongside growth in its energy-device and biostimulator franchises.